학술논문
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
Document Type
article
Author
Emilie Bérard; Christoph Röllig; Sarah Bertoli; Arnaud Pigneux; Suzanne Tavitian; Michael Kramer; Hubert Serve; Martin Bornhäuser; Uwe Platzbecker; Carsten Müller-Tidow; Claudia D. Baldus; David Martínez-Cuadrón; Josefina Serrano; Pilar Martínez-Sánchez; Eduardo Rodríguez Arbolí; Cristina Gil; Juan Bergua; Teresa Bernal; Adolfo de la Fuente Burguera; Eric Delabesse; Audrey Bidet; Pierre-Yves Dumas; Pau Montesinos; Christian Récher
Source
Blood Cancer Journal, Vol 12, Iss 7, Pp 1-8 (2022)
Subject
Language
English
ISSN
2044-5385
Abstract
Abstract In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival. Here, the data from three European registries for 1,199 AML patients aged 70 years or older treated with intensive chemotherapy were used to develop a prognostic scoring system. The median follow-up was 50.8 months. In the training set of 636 patients, age, performance status, secondary AML, leukocytosis, and cytogenetics, as well as NPM1 mutations (without FLT3-ITD), were all significantly associated with overall survival, albeit not to the same degree. These factors were used to develop a score that predicts long-term overall survival. Three risk-groups were identified: a lower, intermediate and higher-risk score with predicted 5-year overall survival (OS) probabilities of ≥12% (n = 283, 51%; median OS = 18 months), 3–12% (n = 226, 41%; median OS = 9 months) and